Cancer Institute A national cancer institute
designated cancer center

Philip W. Lavori

Publication Details

  • PHARMACOTHERAPY OBSERVED IN A LARGE PROSPECTIVE LONGITUDINAL-STUDY ON ANXIETY DISORDERS PSYCHOPHARMACOLOGY BULLETIN Yonkers, K. A., Ellison, J. M., Shera, D. M., Pratt, L. A., Langford, L. M., Cole, J. O., White, K., Lavori, P. W., Keller, M. B. 1992; 28 (2): 131-137


    Data concerning 331 subjects participating in a longitudinal study on anxiety disorders were collected over the first 6 months of the study. Preliminary analyses of somatic treatment according to diagnoses and study site were conducted. The comorbidity of one anxiety disorder with other DSM-III-R diagnoses and other types of anxiety disorders was extensive. Patients with panic disorder received significantly more treatment with a benzodiazepine than patients without panic disorder. Fewer than five percent of the sample were treated with a monoamine oxidase inhibitor. Comorbid depression increased the likelihood of treatment with a newer non-MAOI (non-monoamine oxidase inhibitor), nontricyclic antidepressant. Results suggest a strong effect of treatment site on the pharmacotherapy offered.

    View details for Web of Science ID A1992JG20100003

    View details for PubMedID 1513915

Stanford Medicine Resources:

Footer Links: